Two critical studies, currently underway in the Canadian Parliament, have the potential to significantly impact medical innovation and access to life-saving treatments. These studies, though low-key, could shape the future of healthcare and pandemic preparedness.
The first study, conducted by the Standing Committee on Science and Research, is titled "Private Sector Investment in Research and Development in Canada." However, a closer look reveals a different agenda. It aims to explore ways to commercialize research innovations from Canadian universities, essentially facilitating the transfer of publicly funded research to private hands. This raises concerns about control and access to the fruits of this research, especially when it comes to medications that can mean the difference between life and death.
The second study, soon to commence at the Standing Committee on Health, focuses on "Canada's Pharmaceutical Sovereignty." The COVID-19 pandemic brought this issue to the forefront, highlighting Canada's reliance on other countries for both finished medicines and their ingredients. The pandemic also sparked much-needed public investment in domestic biomanufacturing, but much of this was funneled into private sector companies, including multinationals. This approach, while well-intentioned, may not achieve the desired pharmaceutical sovereignty.
These studies highlight a critical juncture. While public and pharmaceutical interests sometimes align, there are key areas where they diverge. Measures transferring public funds or publicly funded R&D to the private sector must be carefully considered to ensure public investment benefits the public first and foremost. Canada's current approach has largely failed to achieve this balance.
For instance, the University of British Columbia played a pivotal role in developing important COVID-19 innovations, such as the monoclonal antibody treatment bamlanivimab and lipid nanoparticle technology for mRNA vaccines. These innovations, initially funded by the public sector, were then spun off into private companies, which received further public funding for their development. Ultimately, the benefits accrued to private interests, with companies like AbCellera becoming Canada's most valuable biotech, while Canada paid millions for the drug.
Similarly, Canada funded the WHO's mRNA Tech Transfer Hub in South Africa to reverse-engineer mRNA vaccine technology, as pharmaceutical companies refused to voluntarily participate in technology transfer. This highlights the challenges of relying on private industry to bring products to market, especially when their commercial value doesn't match their public health impact.
Numerous WHO-recognized Essential Medicines, including those for deadly diseases like tuberculosis, are not sold in Canada due to their perceived lack of profitability. This leaves patients facing significant challenges in accessing these essential medications. It's a stark reminder that Canada's pharmaceutical sovereignty is not effectively exercised when globally recognized medicines are not readily accessible.
The same challenges are evident in developing new treatments and vaccines. Canadian research breakthroughs often face obstacles in getting out of the lab and into the market due to the profit-driven nature of commercial interests. The saga of the first effective Ebola vaccine, which originated from Canada's National Microbiology Laboratory, is a prime example of how industry reliance can hinder progress. Canada should focus on filling market gaps rather than solely relying on industry.
The past few years have seen multiple outbreaks of serious diseases, all with promising vaccine candidates originating from Canada's NML. However, further funding to advance these innovations has come from foreign governments, not Canada. This highlights the need for Canada to shift its focus from subsidizing a lucrative industry to addressing domestic gaps that commercial interests often ignore.
The Government of Canada has an opportunity to assert its sovereignty and prioritize health over profit. It must identify these gaps and base its actions on health needs, not industry desires. The mere existence of capacity on Canadian soil is not enough. Canada's biomanufacturing investments, while significant, have failed to effectively control how this capacity is used. The publicly owned Biologics Manufacturing Centre in Montreal, for instance, has been sitting idle despite receiving substantial funding.
Canada could simultaneously meet domestic and global needs for important products like mAb treatments with a relatively small investment. This would ensure Canada's own biosecurity stockpiles are well-equipped and help address outbreaks before they reach our shores.
Canada should abandon its current strategy of appeasing private commercial interests and prioritize patients' access to affordable, timely medications. Let's hope these Parliamentary Committees recognize the importance of pharmaceutical sovereignty and support Canadian R&D and biomanufacturing in a way that puts patients first.
